Roche is starting a late-stage trial for Trontinemab, its Alzheimer's drug using brain shuttle tech to clear amyloid. This comes as EU regulators reject approval for Duchenne gene therapy Elevidys. Roche plans to engage further with the agency, reaffirming its belief in the therapy's benefits for children still able to walk.